Asset profile
Telisotuzumab Adizutecan
Antibody–drug conjugate
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2030-09.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
73 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Telisotuzumab Adizutecan: this drug | Phase 3 | Antibody–drug conjugate | MET | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Telisotuzumab Vedotin | Approved | Antibody–drug conjugate | MET | ||
| Tepotinib (Tepmetko) | Approved | Small molecule | MET | ||
| ASKC202 | Phase 3 | Small molecule | MET | ||
| Glumetinib | Phase 3 | Small molecule | MET | ||
| Savolitinib (Orpathys) | Phase 3 | Small molecule | MET | ||
| Vebreltinib | Phase 3 | Small molecule | MET | ||
| ABBV-400 | Phase 2 | Antibody–drug conjugate | MET | ||
| RC108 | Phase 2 | Antibody–drug conjugate | MET | ||
| CKD-703 | Phase 1/2 | Antibody–drug conjugate | MET | ||
| REGN5093 | Phase 1/2 | Monoclonal antibody | MET | ||
| VERT-002 | Phase 1/2 | Monoclonal antibody | MET | ||
| DO-2 | Phase 1 | Small molecule | MET | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK |
…and 58 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(15 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (4)
July 2027 (1)
What to watch
August 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (2)
2029 (3)
May 2029 (1)
What to watch
October 2029 (1)
What to watch
November 2029 (1)
What to watch
2030 (3)
September 2030 (1)
What to watch
October 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (3)
April 2031 (1)
What to watch
June 2031 (1)
What to watch
December 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.